secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092272
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2
--------------------------------------------------------------------

- Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.
- Cash & equivalents $702M as of June 30, 2024; projected runway into first half 2027.
- Sanofi plans to expand KT-474 (IRAK4) Phase 2 trials in HS and AD after interim safety/efficacy review.
- STAT6 degrader KT-621 Phase 1 on track for H2 2024; TYK2 degrader KT-294 Phase 1 in H1 2025.
- KT-253 (MDM2) and KT-333 (STAT3) Phase 1a enrollment completion expected H2 2024 with data presentations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024092272/0000950170-24-092272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024092272/kymr-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer